Document Detail


Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients.
MedLine Citation:
PMID:  8746603     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Hypertension and hypercholesterolemia frequently coexist, necessitating concurrent treatments for both disorders. The present study aimed at evaluating the efficacy, the safety, and the toleration of captopril, an ACE inhibitor, hydrochlorothiazide, a diuretic, and pravastatin, a HMG-CoA reductase inhibitor co-administered in hypertensive patients in general practice. DESIGN: The patients were followed for 16 weeks and asked to comply with a lipid lowering diet for the whole period. Captopril, 50 mg/once daily, was administered alone for the first 4 weeks. Hydrochlorothiazide, 25 mg/day, was added after 4 weeks if required. Pravastatin treatment (20 mg/day) was started at the 8th week of the study and its dose was doubled 4 weeks later if needed. PATIENTS: A total of 603 patients with hypertension (diastolic blood pressure > or = 95 mmHg) and dyslipidemia (total cholesterol > 6.5 mmol/l) were included. SETTING: The study was performed in general practice by 230 physicians. MAIN OUTCOME MEASURE: Determination of blood pressure, circulating levels of total cholesterol, HDL-cholesterol and triglycerides, and blood chemistry for safety monitoring. RESULTS: At the end of the trial 75.1% of patients had their diastolic blood pressure < or = 90 mmHg and 43.5% a total cholesterol level < 6.5 mmol/l. The overall incidence of adverse events was 21.7%, leading to withdrawal in 10.9% of the total number of patients. The combined treatments had no deleterious effect on safety variables. CONCLUSIONS: Captopril, hydrochlorothiazide and pravastatin are effective and well tolerated medications to treat dyslipidemic hypertensive patients.
Authors:
B Waeber; P Greminger; W Riesen; R Darioli; D Simeon-Dubach; R Wunderlin
Related Documents :
11693763 - Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia i...
11881103 - Angiotensin ii receptor blockers and cardiovascular outcomes: the evidence now and in t...
17351163 - Wine, diet, and arterial hypertension.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Blood pressure     Volume:  4     ISSN:  0803-7051     ISO Abbreviation:  Blood Press.     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1996-09-18     Completed Date:  1996-09-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9301454     Medline TA:  Blood Press     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  358-62     Citation Subset:  IM    
Affiliation:
Division d'Hypertension, CHUV, Lausanne, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use
Anticholesteremic Agents / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Captopril / adverse effects,  therapeutic use
Combined Modality Therapy
Diuretics
Drug Therapy, Combination
Enzyme Inhibitors / adverse effects,  therapeutic use*
Female
Humans
Hydrochlorothiazide / adverse effects,  therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias / complications,  diet therapy,  drug therapy*
Hypertension / complications,  diet therapy,  drug therapy*
Male
Middle Aged
Pravastatin / therapeutic use
Prospective Studies
Sodium Chloride Symporter Inhibitors / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticholesteremic Agents; 0/Antihypertensive Agents; 0/Diuretics; 0/Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Sodium Chloride Symporter Inhibitors; 58-93-5/Hydrochlorothiazide; 62571-86-2/Captopril; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Trough-to-peak versus surface ratio in the assessment of antihypertensive agents. APTH Investigators...
Next Document:  Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised con...